Exciting news! The USPTO has just granted our latest patent for branched high-loading AqueaTether® linker technologies. This technology can be used to arm an antibody (or other delivery vehicle) with branched AqT carrying multiple drugs, enabling more effective combination drug treatments for various cancers. This innovation, emerging from our Department of Defense research collaboration, strengthens our drug delivery platform for developing more effective targeted therapies.

This application is the first to be granted under a PCT family WO2019/213046 A1 filing titled “Branched Sugar Alcohol-Based Compounds, and Compositions and Methods Thereof.” The patent represents another milestone in our mission to improve how medicines reach their targets. It adds to our growing IP portfolio of 12 patents and demonstrates our continued leadership in bioconjugation technology.

Special thanks to our research team and our partners at the DOD Breast Cancer Research Program, whose support helped make this breakthrough possible.